In the claims:

1. (Original) A tetrahydrobenzazepine of the general formula I

$$Ar-Y-\overset{O}{\overset{I}{\overset{}{\stackrel{}{\stackrel{}}{\stackrel{}}{\stackrel{}}}}}-B-A$$

$$\overset{O}{\overset{}{\overset{}{\stackrel{}}{\stackrel{}}}}$$

$$N-R^{1}$$

$$(I)$$

in which

- A is a single bond or CH_2 ;
- B is a single bond or a group NR³;
- Y is a single bond, CH₂ or a group NR³, where A, B and Y are not simultaneously a single bond;
- is an aromatic radical which is selected from phenyl and a 5- or 6-membered Ar heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the aromatic radical may have 1, 2 or 3 substituents which are selected independently of one another from C₁-C₆-alkyl which is optionally substituted one or more times by OH, C₁-C₄-alkoxy, halogen or phenyl, or C₂-C₆-alkenyl which is optionally substituted one or more times by OH, C1-C4-alkoxy, halogen or phenyl, or C₂-C₆-alkynyl which is optionally substituted one or more times by OH, C₁-C₄-alkoxy, halogen or phenyl, or C₃-C₆-cycloalkyl which is optionally substituted one or more times by OH, C₁-C₄-alkoxy, halogen, phenyl or C₁-C₄-alkyl, or halogen, CN, OR⁴, COOR⁴, NR⁵R⁶, CONR⁵R⁶, NO₂, SR⁷, SO₂R⁷, SO₂NR⁵R⁶, COR⁸, and phenyl which optionally has one, two or three substituents which are selected independently of one another from C₁-C₄alkyl, C₁-C₄-alkoxy, NR⁵R⁶, CN, C₁-C₂-fluoroalkyl or halogen, where phenyl and the heterocyclic radical may also be fused to a 5- or 6-membered aromatic or nonaromatic carbocycle, or phenyl may be fused to a 5- or 6membered aromatic or nonaromatic heterocycle which has 1, 2 or 3 heteroatoms selected from O, N and S;
- R¹ is hydrogen, C₁-C₈-alkyl, C₁-C₈-haloalkyl, C₂-C₈-alkenyl, C₂-C₈-haloalkenyl, C₂-C₈-alkynyl, C₂-C₈-haloalkynyl, C₁-C₈-alkylcarbonyl, C₁-C₈-haloalkynyl, C₁-C₈-alkyl which carries a substituent which

is selected from OH, C_1 - C_4 -alkoxy, C_1 - C_4 -alkylamino, Di-(C_1 - C_4 -alkyl)amino, phenyl, phenoxy, C_3 - C_8 -cycloalkyl and C_3 - C_8 -cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from OH, CN, NO₂, C_1 - C_4 -alkyl, C_1 - C_4 -haloalkyl, C_1 - C_4 -alkoxy, C_1 - C_4 -haloalkoxy and halogen;

- R² is hydrogen, halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-haloalkyl, C₁-C₄-haloalkoxy, OH, NO₂, CN, COOR⁴, NR⁵R⁶ or CONR⁵R⁶;
- is hydrogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-alkylcarbonyl, phenyl, phenyl-C₁-C₄-alkyl or phenylcarbonyl, where phenyl in the last three radicals mentioned may optionally have 1, 2 or 3 substituents which are selected independently of one another from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and halogen;
- R^4 to R^8 are independently of one another H, C_1 - C_6 -alkyl which may carry a substituent selected from OH, C_1 - C_4 -alkoxy and optionally substituted phenyl, C_1 - C_6 -haloalkyl or phenyl, where R^6 may also be a group COR 9 in which R^9 is H, C_1 - C_6 -alkyl which is optionally substituted by OH, C_1 - C_4 -alkoxy or optionally substituted phenyl, or C_1 - C_6 -haloalkyl or phenyl, where

 R^5 with R^6 may also together with the nitrogen atom to which they are bonded be a 5- or 6-membered saturated or unsaturated N-heterocycle which may optionally have a further heteroatom selected from O, S and NR^{10} as ring member, where R^{10} is hydrogen or C_1 - C_4 -alkyl;

the N-oxides of this compound, the physiologically tolerated acid addition salts of this compound and the physiologically tolerated acid addition salts of the N-oxides of I.

- (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim
 in which A and Y are a single bond, and B is a group NR³.
- 3. (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which A and B together are a single bond, and Y is a group NR³.
- 4. (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which A is CH₂, and B and Y are each a single bond.

- 5. (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim 1, in which Y is CH₂, and A and B together are a single bond.
- 6. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in any of the preceding claims claim 1, in which R² is hydrogen.
- 7. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in any of the preceding claims claim 1, in which Ar is phenyl which may be substituted in the abovementioned manner.
- 8. (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim 7, in which phenyl is unsubstituted or has 1 or 2 substituents, of which one substituent is arranged in the para postion relative to the variable Y.
- 9. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in claim 7 [[or 8]], in which the substituents on the phenyl are selected from C₂-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl and C₁-C₂-fluoroalkyl.
- 10. (Original) A compound as claimed in claim 1, wherein Ar is phenyl which carries a radical R^P which is located in the para position of the phenyl ring wherein R^P has the following formula R^P:

wherein

Y is N, CH or CF,

 R^{a1} and R^{a2} are independently of each other selected from C_1 - C_2 -alkyl, fluorinated C_1 - C_2 -alkyl, provided for Y being CH or CF one of the radicals R^{a1} or R^{a2} may also be hydrogen or fluorine, or

 R^{a1} and R^{a2} form a radical $(CH_2)_m$ wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4.

11. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in any of claims 1 to 6 claim 1, in which Ar is a 5- or 6-membered heteroaromatic radical having 1, 2, 3 or 4 heteroatoms which are selected independently of one another from O, N and S, where the heteroaromatic radical may be substituted in the abovementioned manner.

- 12. (Currently Amended) A tetrahydrobenzazepine of the general formula I as claimed in any of the preceeding claims claim 1, in which R¹ has the general formula CH₂-R¹a in which R¹a is C₁-C₁-alkyl, C₁-C₁-haloalkyl, C₂-C₁-alkenyl, C₂-C₁-haloalkenyl, C₂-C₁-alkynyl, C₂-C₁-haloalkynyl or C₁-C₁-alkyl which has a substituent which is selected from OH, C₁-C₄-alkoxy, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, phenyl, phenoxy, C₃-Cଃ-cycloalkyl and C₃-Cଃ-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and halogen, or C₁-C₄-alkoxy, C₁-C₄-alkylamino, di-C₁-C₄-alkylamino, phenyl, phenoxy, C₃-Cଃ-cycloalkyl or C₃-Cଃ-cycloalkyloxy, where the last four groups mentioned may optionally have one or more substituents selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy and halogen.
- 13. (Original) A tetrahydrobenzazepine of the general formula I as claimed in claim 11, in which R^{1a} is C_1 - C_7 -alkyl, C_2 - C_7 -alkenyl, C_2 - C_7 -alkynyl, C_3 - C_8 -cycloalkyl or C_1 - C_7 -fluoroalkyl.
- 14. (Original) A tetrahydrobenzazepine as claimed in claim 12 of the general formula I.A/B

$$R^{p}$$
 \longrightarrow $N-R^{1}$ (I.A/B)

in which

- Q is CH₂ or NR³,
- R¹ is a group CH₂-R^{1a} in which R^{1a} has the meanings indicated in claim 11, and
- R^P is C₂-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₁-C₄-fluoroalkyl.
- 15. (Original) A tetrahydrobenzazepine as claimed in claim 14, in which R^{1a} is selected from methyl, ethyl, fluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl or vinyl and R^P is selected from ethyl, vinyl, isopropyl, tert-butyl and trifluoromethyl.

16. (Original) A tetrahydrobenzazepine as claimed in claim 14, wherein R^P is selected from a radical of the formula

wherein

Y is N, CH or CF,

 R^{a1} and R^{a2} are independently of each other selected from C_1 - C_2 -alkyl, fluorinated C_1 - C_2 -alkyl, provided for Y being CH or CF one of the radicals R^{a1} or R^{a2} may also be hydrogen or fluorine, or

 R^{a1} and R^{a2} form a radical $(CH_2)_m$ wherein 1 or 2 of the hydrogen atoms may be replaced by fluorine and wherein m is 2, 3 or 4; and R^{1a} is ethyl.

- 17. (Original) A tetrahydrobenzazepine as claimed in claim 16, wherein R^P is selected from isopropyl, (R)-1-fluoroethyl, (S)-1-fluoroethyl, 2-fluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2-trifluoroethyl, (R)-1-fluoropropyl, (S)-1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1,1-difluoropropyl, 2,2-difluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, (R)-2-fluoro-1-methylethyl, (S)-2-fluoro-1-methylethyl, (R)-2,2-difluoro-1-methylethyl, (S)-2,2-difluoro-1-methylethyl, (R)-1,2-difluoro-1-methylethyl, (S)-1,2-difluoro-1-methylethyl, (R)-2,2,2-trifluoro-1-methylethyl, 1-(fluoromethyl)-2,2-difluoroethyl, 1-fluoro-1-methylethyl, cyclopropyl, cyclobutyl, 1-fluorocyclopropyl, 2,2-difluorocyclopropyl and 2-fluorocyclopropyl.
- 18. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient selected from compound of the general formula I as claimed in any of claims 1 to 17 claim 1, the physiologically tolerated acid addition salts of I, the N-oxides of compounds of the general formula I, and the physiologically tolerated acid addition salts of the N-oxides of I, where appropriate together with physiologically acceptable carriers and/or excipients.
- 19. (Currently Amended) The use of at least one compound of the general formula I as claimed in any of claims 1 to 15 claim 1, its acid addition salts, its N-oxides and the acid addition salts of the N-oxides for producing a pharmaceutical composition for the treatment of disorders which respond to the influence of dopamine D₃ receptor antagonists or agonists.

- 20. (Original) The use as claimed in claim 19 for the treatment of disorders of the central nervous system.
- 21. (Original) The use as claimed in claim 19 for the treatment of renal function disorders.
- 22. (Original) A method for treating a medical disorder susceptible to treatment with a dopamine D3 receptor ligand, said method comprising administering an effective amount of at least one compound as claimed in claim 1 to a subject in need thereof.
- 23. (Original) The method as claimed in claim 22, wherein the medical disorder is a disease of the central nervous system.